Answers are grounded in this paper and cite their sources.
Systematic review evaluates treatment outcomes in children with SJS/TEN, indicating a need for guidelines.
Although Stevens–Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare, their impact on children is disproportionately severe, with recent US data suggesting a rising incidence of 0.5–6.3 cases per 100,000 children annually. Pediatric SJS/TEN is characterized by substantial mortality, long-term physical and psychological sequelae, and frequent overlap features that complicate diagnosis. Despite this, pediatric-specific evidence is scarce. Ethical constraints preclude randomized controlled trials (RCTs), leaving clinicians without consensus guidelines on systemic therapies. To address this gap, we systematically reviewed real-world treatment approaches and outcomes in pediatric SJS/TEN.
No takes yet. Share an insight, caveat, or question.
Chiu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: